Exact Mass: 543.1804
Exact Mass Matches: 543.1804
Found 363 metabolites which its exact mass value is equals to given mass value 543.1804
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Doxorubicin
Doxorubicin is only found in individuals that have used or taken this drug. It is antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of daunorubicin. [PubChem]Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors KEIO_ID D064
phosphoramidon
A dipeptide isolated from the cultures of Streptomyces tanashiensis. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors KEIO_ID P122
dTDP-alpha-D-forosamine
A pyrimidine nucleotide-sugar having thymine as the nucleobase and alpha-D-forosamine as the sugar component.
Epirubicin
Epirubicin is only found in individuals that have used or taken this drug. It is an anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. [PubChem]Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors Same as: D07901
Puromycin hydrochloride
Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis[1].
Carboxymethyl chitosan
Monohydroxytriacetyltaxine
Triferric doxorubicin
Phosphoramidon
Doxorubicin
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors
Epirubicin
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent An anthracycline that is the 4-epi-isomer of doxorubicin. D004791 - Enzyme Inhibitors Same as: D07901
Ala His Met Trp
Ala His Trp Met
Ala Met His Trp
Ala Met Trp His
Ala Trp His Met
Ala Trp Met His
Cys Cys Arg Tyr
Cys Cys Tyr Arg
Cys Glu His Arg
Cys Glu Arg His
Cys Phe Phe Gln
Cys Phe Gln Phe
Cys His Glu Arg
Cys His Arg Glu
Cys His Val Trp
Cys His Trp Val
Cys Lys Met Tyr
Cys Lys Tyr Met
Cys Met Lys Tyr
Cys Met Gln Tyr
Cys Met Tyr Lys
Cys Met Tyr Gln
Cys Gln Phe Phe
Cys Gln Met Tyr
Cys Gln Tyr Met
Cys Arg Cys Tyr
Cys Arg Glu His
Cys Arg His Glu
Cys Arg Tyr Cys
Cys Val His Trp
Cys Val Trp His
Cys Trp His Val
Cys Trp Val His
Cys Tyr Cys Arg
Cys Tyr Lys Met
Cys Tyr Met Lys
Cys Tyr Met Gln
Cys Tyr Gln Met
Cys Tyr Arg Cys
Asp His Ser Trp
Asp His Trp Ser
Asp Ser His Trp
Asp Ser Trp His
Asp Trp His Ser
Asp Trp Ser His
Glu Cys His Arg
Glu Cys Arg His
Glu His Cys Arg
Glu His Met Gln
Glu His Gln Met
Glu His Arg Cys
Glu Met His Gln
Glu Met Gln His
Glu Gln His Met
Glu Gln Met His
Glu Arg Cys His
Glu Arg His Cys
Phe Cys Phe Gln
Phe Cys Gln Phe
Phe Phe Cys Gln
Phe Phe Gln Cys
Phe Gln Cys Phe
Phe Gln Phe Cys
His Ala Met Trp
His Ala Trp Met
His Cys Glu Arg
His Cys Arg Glu
His Cys Val Trp
His Cys Trp Val
His Asp Ser Trp
His Asp Trp Ser
His Glu Cys Arg
His Glu Met Gln
His Glu Gln Met
His Glu Arg Cys
His His His Asn
His His Asn His
His Met Ala Trp
His Met Glu Gln
His Met Gln Glu
His Met Trp Ala
His Asn His His
His Gln Glu Met
His Gln Met Glu
His Arg Cys Glu
His Arg Glu Cys
His Ser Asp Trp
His Ser Trp Asp
His Val Cys Trp
His Val Trp Cys
His Trp Ala Met
His Trp Cys Val
His Trp Asp Ser
His Trp Met Ala
His Trp Ser Asp
His Trp Val Cys
Lys Cys Met Tyr
Lys Cys Tyr Met
Lys Met Cys Tyr
Lys Met Tyr Cys
Lys Tyr Cys Met
Lys Tyr Met Cys
Met Ala His Trp
Met Ala Trp His
Met Cys Lys Tyr
Met Cys Gln Tyr
Met Cys Tyr Lys
Met Cys Tyr Gln
Met Glu His Gln
Met Glu Gln His
Met His Ala Trp
Met His Glu Gln
Met His Gln Glu
Met His Trp Ala
Met Lys Cys Tyr
Met Lys Tyr Cys
Met Gln Cys Tyr
Met Gln Glu His
Met Gln His Glu
Met Gln Tyr Cys
Met Trp Ala His
Met Trp His Ala
Met Tyr Cys Lys
Met Tyr Cys Gln
Met Tyr Lys Cys
Met Tyr Gln Cys
Asn His His His
Gln Cys Phe Phe
Gln Cys Met Tyr
Gln Cys Tyr Met
Gln Glu His Met
Gln Glu Met His
Gln Phe Cys Phe
Gln Phe Phe Cys
Gln His Glu Met
Gln His Met Glu
Gln Met Cys Tyr
Gln Met Glu His
Gln Met His Glu
Gln Met Tyr Cys
Gln Tyr Cys Met
Gln Tyr Met Cys
Arg Cys Cys Tyr
Arg Cys Glu His
Arg Cys His Glu
Arg Cys Tyr Cys
Arg Glu Cys His
Arg Glu His Cys
Arg His Cys Glu
Arg His Glu Cys
Arg Tyr Cys Cys
Ser Asp His Trp
Ser Asp Trp His
Ser His Asp Trp
Ser His Trp Asp
Ser Trp Asp His
Ser Trp His Asp
Val Cys His Trp
Val Cys Trp His
Val His Cys Trp
Val His Trp Cys
Val Trp Cys His
Val Trp His Cys
Trp Ala His Met
Trp Ala Met His
Trp Cys His Val
Trp Cys Val His
Trp Asp His Ser
Trp Asp Ser His
Trp His Ala Met
Trp His Cys Val
Trp His Asp Ser
Trp His Met Ala
Trp His Ser Asp
Trp His Val Cys
Trp Met Ala His
Trp Met His Ala
Trp Ser Asp His
Trp Ser His Asp
Trp Val Cys His
Trp Val His Cys
Tyr Cys Cys Arg
Tyr Cys Lys Met
Tyr Cys Met Lys
Tyr Cys Met Gln
Tyr Cys Gln Met
Tyr Cys Arg Cys
Tyr Lys Cys Met
Tyr Lys Met Cys
Tyr Met Cys Lys
Tyr Met Cys Gln
Tyr Met Lys Cys
Tyr Met Gln Cys
Tyr Gln Cys Met
Tyr Gln Met Cys
Tyr Arg Cys Cys
Puromycin dihydrochloride
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis[1].
4-METHOXYPHENYL 3-O-ALLYL-4,6-O-BENZYLIDENE-2-DEOXY-2-PHTHALIMIDO-BETA-D-GLUCOPYRANOSIDE
GSK461364
sodium 2-[[5-cyano-2,6-bis[(3-methoxypropyl)amino]-4-methyl-3-pyridyl]azo]-5-nitrobenzenesulphonate
1,2-dihydro-6-hydroxy-4-methyl-2-oxo-5-[[4-(phenylazo)phenyl]azo]-1,3-bipyridinium malate
2-[2-[2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethoxy]ethoxy]ethanol
2-[2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethoxy]ethanol Fumarate
2-{4-[(2S)-2-[({[(1S)-1-Carboxy-2-phenylethyl]amino}carbonyl)amino]-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid
Sulfamethoxazole; Trimethoprim
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EE - Combinations of sulfonamides and trimethoprim, incl. derivatives D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D013424 - Sulfanilamides Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Phosphoramidon
(1R,2R,4S)-4-[(3-azaniumyl-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-2-ethyl-2,5,7,12-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
(2S)-2-[[(2R)-2-[[hydroxy-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
(7S,9S)-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-OMe
(7S,9S)-7-[[(4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
6-(4-Benzylpiperazine-1-carbonyl)-2-[3-(trifluoromethyl)phenyl]benzo[de]isoquinoline-1,3-dione
2-O-methyl-alpha-L-fucopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galactopyranose
2-O-methyl-alpha-L-fucopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-galactopyranose
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
(1R)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyridinyl)methyl]-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide
N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
(1S)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-(1-oxo-2-pyridin-4-ylethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide
(1R)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-(1-oxo-2-pyridin-4-ylethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide
(1S)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyridinyl)methyl]-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(7R,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-Carboxy-13-deoxycarminomycin
An anthracycline antibiotic that is 13-deoxycarminomycin substituted at position 10 by a carboxy group.
7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-carboxy-13-deoxycarminomycin zwitterion
A zwitterion obtained by transfer of a proton from the carboxy to the primary amino group of 10-carboxy-13-deoxycarminomycin; major species at pH 7.3.
5'-Guanidinonaltrindole (hydrochloride)
5'-Guanidinonaltrindole (5'-GNTI) hydrochloride is a highly selective and potent κ-opioid receptor antagonist with a Ki of 0.18 nM for human κ-opioid receptor[1].